Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 12:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 101 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Magnetic Resonance Imaging Contrast Agents Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent

NCT05413668
View directory record Official record
Conditions
Healthy
Interventions
RVP-001, Placebo
Drug
Lead sponsor
Reveal Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Jul 21, 2026, 12:32 PM EDT
Terminated No phase listed Observational

Metastatic Colorectal Cancer: Treatment Response With Dynamic Contrast MRI

NCT00820456
View directory record Official record
Conditions
Colorectal Neoplasm, Hepatic Neoplasm
Interventions
DCE-MRI
Other
Lead sponsor
American College of Radiology
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Phase 4 Interventional

DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function

NCT00401687
View directory record Official record
Conditions
Ventricular Ejection Fraction
Interventions
Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Washington DC, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2011 · Synced Jul 21, 2026, 12:32 PM EDT
Completed No phase listed Observational

Multicenter Myocardial Viability Trial

NCT00661232
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
CHI St. Luke's Health, Texas
Other
Eligibility
21 Years to 85 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Not applicable Interventional

Indirect Magnetic Resonance Lymphangiography of the Head and Neck Region Using Conventional Gadolinium-based Contrast

NCT00230295
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Cancers
Interventions
IMR LAG
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Jul 21, 2026, 12:32 PM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Phase 3 Interventional

A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Known or Suspected Brain or Spinal Cord-related Problems

NCT05915702
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Central Nervous System Pathology
Interventions
Gadoquatrane (BAY1747846), Gadobutrol, Gadoterate meglumine, Gadoteridol
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Indian Wells, California • Orange, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jul 21, 2026, 12:32 PM EDT
Enrolling by invitation Not applicable Interventional

Evaluation of Gadolinium Based Contrast Agents for Portable MR Imaging Systems

NCT07296263
View directory record Official record
Conditions
Intra-axial Tumors, Extra-axial Tumors, Infection/Inflammatory Lesions
Interventions
Portable MRI (pMRI), Gadolinium-Based Contrast Agent (GBCA)
Device · Drug
Lead sponsor
Hyperfine
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Altamonte Springs, Florida • Boston, Massachusetts • Amherst, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 21, 2026, 12:32 PM EDT
Completed No phase listed Observational

Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography

NCT03910114
View directory record Official record
Conditions
Magnetic Resonance Imaging Contrast Agents
Interventions
Magnevist, Dotarem, Gadovist
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Up to 21 Years
Enrollment
500 participants
Timeline
1990 – 2019
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Not applicable Interventional

Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery

NCT03070340
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast Magnetic Resonance Imaging (MRI), Contrast Enhanced Mammography (CEDM)
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Female only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Jul 21, 2026, 12:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging

NCT00861848
View directory record Official record
Conditions
Kawasaki Disease, Heart Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
12 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Not applicable Interventional

Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer

NCT03176979
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Contrast Agent, Digital Tomosynthesis Mammography, Dual-Energy Contrast-Enhanced Digital Spectral Mammography
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Jul 21, 2026, 12:32 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Gadoterate in Patients With Renal Dysfunction

NCT02382380
View directory record Official record
Conditions
Renal Dysfunction
Interventions
Gadoterate, No Gadoterate
Drug · Other
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 21, 2026, 12:32 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

DCE MRI in Patients With Pancreatic Cancer

NCT02070705
View directory record Official record
Conditions
Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Results available

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

NCT01544166
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadobutrol (Gadavist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Savannah, Georgia • Chicago, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 21, 2026, 12:32 PM EDT
Completed No phase listed Observational

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

NCT05350189
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Interventions
Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
1,602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 31, 2024 · Synced Jul 21, 2026, 12:32 PM EDT
Completed No phase listed Observational

Motion Correction in Dynamic Contrast Enhanced Magnetic Resonance Imaging (MRI) in Ovarian Cancer: A Pilot Study

NCT00946140
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DCE-MRI scans
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Not applicable Interventional

Pilot Study: Dynamic Contrast-enhanced Magnetic Resonance Imaging(DCE-MRI)for Assessing Tumor Vascularity and Permeability in Soft Tissue Sarcoma Treated With Preoperative Radiotherapy Followed by Surgical Resection

NCT01575951
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
MRI-DCE
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 21, 2026, 12:32 PM EDT
Completed No phase listed Observational

Assessment of Wall Thickness in Hypertrophic Cardiomyopathy

NCT02234336
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Noncontrast echocardiography, Contrast Echocardiography, Cardiac magnetic resonance imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics (How it Moves Into, Through and Out From the Body) of a New Gadolinium-based Contrast Agent (GBCA) After Injection and How Safe it is in Participants With Normal and Impaired Renal Function

NCT05061979
View directory record Official record
Conditions
Contrast Enhancement in Magnetic Resonance Imaging
Interventions
BAY1747846
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Jul 21, 2026, 12:32 PM EDT
Terminated Not applicable Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

NCT01599832
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Phase 1 Interventional

Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging

NCT02311556
View directory record Official record
Conditions
Brain Metastases
Interventions
dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Jul 21, 2026, 12:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography

NCT03173066
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Ferumoxytol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 21, 2026, 12:32 PM EDT
Terminated Phase 3 Interventional Results available

Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)

NCT00845702
View directory record Official record
Conditions
Renal Artery Stenosis
Interventions
Gadoterate meglumine (Dotarem), Time of Flight Magnetic Resonance Angiography
Drug · Other
Lead sponsor
Guerbet
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Jul 21, 2026, 12:32 PM EDT